Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Biocept, Inc. (BIOC) Business Update Conference Call (Transcript) | seekingalpha.com • |
Biocept to Hold Business Update Conference Call on August 30, 2023 | businesswire.com • |
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole | investorplace.com • |
Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference | proactiveinvestors.com • |
Biocept appoints Antonino Morales as president and chief executive officer | proactiveinvestors.com • |
Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023 | businesswire.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2023-11-20 | 2023-09 | 0 | N/A | N/A | N/A |
2023-05-10 | 2023-03 | 0 | N/A | N/A | N/A |
2023-04-17 | 2022-12 | 0 | N/A | N/A | N/A |
2022-11-21 | 2022-09 | -4.8 | N/A | N/A | N/A |
2022-11-10 | 2022-06 | 0 | N/A | N/A | N/A |
2022-05-23 | 2022-03 | -7.21 | N/A | N/A | N/A |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-12-08 | HALE DAVID F | Director | 0.00 | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Anson Funds Management LP | 44.86K | 54.28K | 1.71% |
2023-06-29 | Boothbay Fund Management, LLC | 23.53K | 28.47K | 0.90% |
2023-06-29 | Tower Research Capital LLC (TRC) | 5.39K | 6.52K | 0.21% |
2023-06-29 | Blackrock Inc. | 5.26K | 6.37K | 0.20% |
2023-06-29 | Acadian Asset Management. LLC | 247.00 | 298.00 | 0.01% |
2023-06-29 | Group One Trading, L.P. | 270.00 | 326.00 | 0.01% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 4.43K | 5.37K | 0.17% |
2023-05-30 | Fidelity Extended Market Index Fund | 2.95K | 6.38K | 0.11% |
2023-05-30 | Fidelity Series Total Market Index Fund | 644.00 | 1.39K | 0.02% |
2023-05-30 | Fidelity Total Market Index Fund | 488.00 | 1.05K | 0.02% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 189.00 | 408.00 | 0.01% |
Split | Date |
---|---|
1 : 30 | 2023-05-17 |
1 : 10 | 2020-09-08 |
1 : 30 | 2018-07-10 |
1 : 3 | 2016-09-29 |
-
I knew they were gonna merge the COVID testing is way to lucrative
-
MSNBC JUST SAID THERMO - BIOCEPT MERGER IN THE WORKS !!!! I knew it!!!!!!
-
Just came on msnbc thermo -biocept merger in the works !!!!!!!!
-
I hope all the losers that sell go broke they all deserve it
-
Fuck ya lol finally sorry for cursing
-
Either you idiots are going to keep buying what are you gonna let it keep going down all the other idiots are the shorts if we all keep buying we could put your silver dollar and I’ll get Rich right now let’s do it
-
I smell an offering
-
Why do you true believers listen to these shorts that act like they care everything they say is bs
-
This stock is trash
-
All we gotta do is all buy right now 500 shares it will start momentum
-
This stock is guaranteed for shorts goes to 80 every day then negative. True believers let’s all buy 1000 shares right now
-
If we all buy 1000 shares we can get something going !!!!!!
-
Shorting should b illegal
-
R u guys on crack saying this shit stock is moving every time you say it crashes just stop and block the shorts if u want it to jump
-
I am hoping the best for everybody with the stock however I believe it is going to dump like a turd in the toilet bowl. Do you have a penny flippers flipping hard in here short sellers gearing up because of their loss on Kodak. So please be aware that if you have any Shares greater than 100 I would consider securing profits and getting out now.
-
$BIOC we need to buy the ask the short are trying to pull it down less than 1/10 cent diff between bid and ask
-
$BIOC slap the ask a few times
-
-
Check ECOR FDA approval. Gonna blow!
-
-
Biocept, Inc. (BIOC) Business Update Conference Call (Transcript)
seekingalpha.com • -
Biocept to Hold Business Update Conference Call on August 30, 2023
businesswire.com • -
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
investorplace.com • -
Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference
proactiveinvestors.com • -
Biocept appoints Antonino Morales as president and chief executive officer
proactiveinvestors.com • -
Why Is Biocept (BIOC) Stock Down 42% Today?
investorplace.com • -
Biocept shares to commence trading on split-adjusted basis
proactiveinvestors.com • -
Biocept, Inc. (BIOC) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
Biocept reports 176% year-over-year jump in orders for CNSide assay
proactiveinvestors.com • -
Biocept adds CPA Quyen Dao-Haddock to board, bringing extensive financial acumen to audit committee
proactiveinvestors.com • -
Biocept to use CNSide assay in study looking at biomarkers in patients with metastatic breast cancer
proactiveinvestors.com • -
Biocept to Hold Business Strategy Conference Call Today
businesswire.com • -
Biocept sees 1Q net revenue rise 12% driven by its coronavirus testing services
proactiveinvestors.com • -
Biocept, Inc. says coronavirus testing drove strong rise in full-year 2021 revenue
proactiveinvestors.com • -
Biocept reports unaudited net revenue of $61.2 million for 2021
proactiveinvestors.com • -
Biocept appoints Samuel Riccitelli as its interim CEO and Antonino Morales as interim CFO
proactiveinvestors.com • -
Biocept appoints Darrell Taylor as its new chief compliance officer
proactiveinvestors.com • -
Biocept says demand for its COVID-19 RT-PCR testing increases in 2022 amid Omicron variant surge
proactiveinvestors.com • -
Biocept launches single test for COVID-19 and Influenza as cases rise during flu season
proactiveinvestors.com • -
Biocept sees profitability in third quarter thanks to increased RT-PCR COVID-19 testing
proactiveinvestors.com • -
7 of the Best Penny Stocks to Buy Coming Into Year-End
investorplace.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept reports profitability for the first half on back of increased COVID-19 testing
proactiveinvestors.com • -
Biocept appoints David Karlander as senior vice president of Commercial Operations
proactiveinvestors.com • -
Biocept bolsters board of directors and names Samuel D Riccitelli as new chairman
proactiveinvestors.com • -
Biocept joins the Russell Microcap Index
proactiveinvestors.com • -
Biocept Joins the Russell Microcap® Index
businesswire.com • -
Wall Street takes a turn for the worse as investors eye Fed
proactiveinvestors.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept makes coronavirus testing available for California's 116 community colleges
proactiveinvestors.com • -
Biocept launches its CNSide cerebrospinal fluid assay for early detection of metastatic brain cancer
proactiveinvestors.com • -
Biocept says its lab received to-date more than 350,000 coronavirus testing samples for processing
proactiveinvestors.com • -
Biocept: Record Revenues And Profits Support Speculative Buy
seekingalpha.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept: Q4 Earnings Insights
benzinga.com • -
Biocept to Participate in Three Virtual Investment Conferences in March
businesswire.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept to Present at H.C. Wainwright Virtual BioConnect Conference
prnewswire.com • -
Analyzing Teleflex (NYSE:TFX) & Viatar CTC Solutions (NYSE:VRTT)
thelincolnianonline.com •